• Revenue increased 85% to $12.1 million
• Net loss reduced by 27% to $16.8 million
• Successful $11.6 million capital raise completed

CurveBeam AI Limited has released its preliminary final report for the year ended 30 June 2025. The company reported revenue of $12,096,583, an increase of 85% compared to the previous year. The net loss for the year was $16,842,748, a reduction of 27% compared to the prior year. The improved financial performance was driven by a net increase in gross margin of $2.42 million due to the increase in revenue, a decrease in human resource costs of $1.12 million due to a restructure, and a decrease in consulting and professional fees of $1.23 million primarily due to IPO and other one-off costs in the comparative period. The company also reported an increase in other income of $0.91 million, primarily related to an increase in R&D rebate. These positive variances were offset by increases in other expenditure, including one-off bad debt expenses and increased travel and marketing expenditure to support the growth of the business. During the year, the company completed a $11.58 million capital raise through a placement and accelerated non-renounceable entitlement offer, which will support the company's ongoing operations and strategic initiatives. The directors have prepared the financial report on a going concern basis, noting that the continuing viability of the group is dependent on completing the validation of the enhanced HiRiseTM device, generating increased revenue, and obtaining additional funding.

The company is targeting increased revenue, primarily driven by enhanced HiRiseTM placements through near-term market opportunities, along with restrained and ongoing management of costs. In the mid-term, the company will balance generating increased margins from revenue growth with strategic investments.

The company continues to validate the enhanced HiRiseTM for use with a major robotic aided surgical system in knee and hip surgery. The validation of the enhanced HiRiseTM is anticipated to help overcome a major hurdle that has hindered HiRiseTM device placements in both the current period and the comparative period.